Kyu Chae

Array ( [id] => 11528653 [patent_doc_number] => 20170088631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-30 [patent_title] => 'NOVEL IMMUNOCONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/200507 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 51828 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15200507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13117937 [patent_doc_number] => 10077313 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-18 [patent_title] => Anti-CD123 antibodies and conjugates and derivatives thereof [patent_app_type] => utility [patent_app_number] => 15/195401 [patent_app_country] => US [patent_app_date] => 2016-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 54 [patent_no_of_words] => 62425 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11092354 [patent_doc_number] => 20160289323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13' [patent_app_type] => utility [patent_app_number] => 15/180916 [patent_app_country] => US [patent_app_date] => 2016-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 20754 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15180916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436102 [patent_doc_number] => 20170037123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'ANTI-HUMAN IL-21 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/177914 [patent_app_country] => US [patent_app_date] => 2016-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23820 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15177914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20593621 [patent_doc_number] => 12577323 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Compositions and conjugates comprising an interleukin and polypeptides that specifically bind TGF-beta [patent_app_type] => utility [patent_app_number] => 15/735158 [patent_app_country] => US [patent_app_date] => 2016-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 12 [patent_no_of_words] => 13942 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15735158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12091297 [patent_doc_number] => 20170348389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'TREATING LIVER DISEASES WITH INTERLEUKIN 24' [patent_app_type] => utility [patent_app_number] => 15/173570 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17483 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15173570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448572 [patent_doc_number] => 09982043 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Use of IL-20 antagonists for treating pancreatic cancer [patent_app_type] => utility [patent_app_number] => 15/173560 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15606 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15173560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15571545 [patent_doc_number] => 10576131 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-03 [patent_title] => IL-23-p19 vaccines [patent_app_type] => utility [patent_app_number] => 15/569303 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11864 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15569303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808771 [patent_doc_number] => 20180161427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => COMBINATION OF AN ANTI-IL-10 ANTIBODY AND A CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/577377 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386471 [patent_doc_number] => 20180244777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => Novel Treatment Methods Based on Multifunctional Molecules [patent_app_type] => utility [patent_app_number] => 15/575049 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15575049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13106851 [patent_doc_number] => 10072058 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates [patent_app_type] => utility [patent_app_number] => 15/142169 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 14 [patent_no_of_words] => 11503 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15142169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053379 [patent_doc_number] => 20160250340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'POLYMER CONJUGATES OF INTERFERON BETA-1a AND USES' [patent_app_type] => utility [patent_app_number] => 15/131233 [patent_app_country] => US [patent_app_date] => 2016-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 20224 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15131233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11083782 [patent_doc_number] => 20160280747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'ANTICALINS' [patent_app_type] => utility [patent_app_number] => 15/092566 [patent_app_country] => US [patent_app_date] => 2016-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16008 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15092566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12676015 [patent_doc_number] => 20180117171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS [patent_app_type] => utility [patent_app_number] => 15/563878 [patent_app_country] => US [patent_app_date] => 2016-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15975697 [patent_doc_number] => 10668150 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same [patent_app_type] => utility [patent_app_number] => 15/562228 [patent_app_country] => US [patent_app_date] => 2016-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 61 [patent_no_of_words] => 93775 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15562228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15913057 [patent_doc_number] => 10653750 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Use of CCL2 to inhibit abnormal uterine bleeding [patent_app_type] => utility [patent_app_number] => 15/561158 [patent_app_country] => US [patent_app_date] => 2016-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 32 [patent_no_of_words] => 11587 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10997435 [patent_doc_number] => 20160194381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATMENT OF RETINOID-RESPONSIVE CONDITIONS' [patent_app_type] => utility [patent_app_number] => 15/077035 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 18045 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15077035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12904603 [patent_doc_number] => 20180193376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS [patent_app_type] => utility [patent_app_number] => 15/558491 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11434831 [patent_doc_number] => 20170035852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'METHODS AND USE OF GROWTH HORMONE SUPERGENE FAMILY PROTEIN ANALOGS FOR TREATMENT OF RADIATION EXPOSURE' [patent_app_type] => utility [patent_app_number] => 15/073246 [patent_app_country] => US [patent_app_date] => 2016-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 23914 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15073246 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605960 [patent_doc_number] => 10906952 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 15/556282 [patent_app_country] => US [patent_app_date] => 2016-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 26 [patent_no_of_words] => 26238 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15556282 [rel_patent_id] =>[rel_patent_doc_number] =>)